Table 2.
Supportive care agents by drug class administered within 5 days of onset of nausea/vomiting and outcomes of patients after intervention.
| No supportive care | Serotonin receptor antagonist | Dopamine receptor (D2/D3) antagonist | NK1 antagonist | Benzodiazepine | GR receptor agonist | Cannabinoid receptor agonist | Histamine (H1) receptor agonist | Olanzapine | |
|---|---|---|---|---|---|---|---|---|---|
| N (%) of patients with any grade nausea/vomiting | 217 (69%) | 118 (38%) | 54 (17%) | 25 (8%) | 26 (8%) | 39 (12%) | 10 (3%) | 18 (6%) | 13 (4%) |
| Grade 1 N (%) | 97 (45%) | 61 (52%) | 29 (54%) | 9 (36%) | 10 (39%) | 16 (41%) | 1 (10%) | 6 (33%) | 5 (39%) |
| Grade 2 N (%) | 104 (48%) | 47 (40%) | 19 (35%) | 10 (40%) | 13 (50%) | 21 (54%) | 7 (70%) | 10 (56%) | 7 (54%) |
| Grade 3 N (%) | 16 (7%) | 10 (9%) | 6 (11%) | 6 (24%) | 3 (12%) | 2 (5%) | 2 (20%) | 2 (11%) | 1 (8%) |
| AEs resolved/resolving N (%) | 122 (56%) | 70 (59%) | 35 (65%) | 18 (72%) | 18 (69%) | 14 (36%) | 9 (90%) | 10 (56%) | 10 (77%) |
| AEs Not resolved/resolving N (%) | 95 (44%) | 48 (41%) | 19 (35%) | 7 (28%) | 8 (31%) | 25 (64%) | 1 (10%) | 8 (44%) | 3 (23%) |
| Median duration of event for resolved/resolving nausea/vomiting (days; Q1, Q3) | 22 (6, 51) | 8 (4, 29) | 7 (3, 29) | 9 (2, 53) | 6 (3, 72) | 13 (1, 31) | 12 (8, 20) | 11 (3, 23) | 15 (5, 45) |
Incidence and severity of nausea/vomiting at the time of supportive care with outcomes of patients who had intervention within 5 days of AE onset. Supportive care agents per drug class: serotonin (5-HT3) receptor agonist (granisetron, mirtazapine, ondansetron, palonosetron), dopamine (D2/D3) receptor antagonist (alizapride, domperidone, haloperidol, metoclorpramide, prochloroperazine, thiethylperazine maleate, trimethobenzamide), neurokinin 1 (NK1) receptor antagonists (rolapitant, aprepitant, fosaprepitant), benzodiazepine (clonazepam, diazepam, lorazepam), glucocorticoid receptor (GR) agonist (dexamethasone, prednisolone, prednisone), cannabinoid receptor agonist (dronabinol, nabilone, and cannabis sativa), and histamine (H1) receptor agonist (cyclizine, dimenhydrinate, diphenhydramine, meclizine, promethazine).